Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05585034
Title Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors
Recruitment Recruiting
Gender
Phase Phase I
Variant Requirements No
Sponsors Xencor, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UCLA Hematology/Oncology RECRUITING Los Angeles California 90095 United States Details
Sarah Cannon Research Institute at HealthONE RECRUITING Denver Colorado 80218 United States Details
Florida Cancer Specialists RECRUITING Sarasota Florida 34232 United States Details
Winship Cancer Institute, Emory University RECRUITING Atlanta Georgia 30322 United States Details
Northwestern Memorial Hospital RECRUITING Chicago Illinois 60611 United States Details
Columbia University Irvine Medical Center RECRUITING New York New York 10032 United States Details
University of Cincinnati Medical Center RECRUITING Cincinnati Ohio 45219 United States Details
UPMC Hillman Cancer Center RECRUITING Pittsburgh Pennsylvania 15213 United States Details
Tennessee Oncology RECRUITING Nashville Tennessee 37203 United States Details
The University of Texas MD Anderson Cancer Center RECRUITING Houston Texas 77030 United States Details
Huntsman Cancer Institute, University of Utah RECRUITING Salt Lake City Utah 84112 United States Details
Froedtert Hospital & The Medical College of Wisconsin RECRUITING Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field